Physician profile
Weiming Wang
NPI 1821726498
$3,281.95
in general payments reported to CMS, 2019-2025
19 companies · $608 in 2025
The $608 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $91.75 · 2023: $1,647 · 2024: $935 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,168 · Education: $22.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,167.68 |
| Education | $22.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,227.68 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $620.54 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $208.08 | 2023-2025 | Aristada, Lybalvi |
| Astrazeneca Pharmaceuticals LP | $160.91 | 2023-2024 | Farxiga, Breztri |
| Lilly USA, LLC | $147.26 | 2022-2023 | Emgality, Jardiance |
| Abbvie INC. | $140.49 | 2023-2024 | |
| Horizon Therapeutics Plc | $122.43 | 2023 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.33 | 2023 | Jardiance |
| Esperion Therapeutics, INC. | $116.86 | 2023 | Nexletol, Nexlizet |
| Almatica Pharma LLC | $115.04 | 2023-2024 | Gralise, Loreev Xr, Teriparatide |
| Amarin Pharma, INC. | $71.89 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $53.53 | 2025 | Cobenfy |
| Bayer Healthcare Pharmaceuticals INC. | $48.55 | 2023 | |
| Gilead Sciences, INC. | $29.70 | 2023 | |
| Lundbeck LLC | $22.84 | 2024 | Abilify Maintena |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $22.52 | 2023 | Rayaldee |
| Idorsia Pharmaceuticals US INC | $19.44 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $18.62 | 2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $15.24 | 2023 | Seglentis, Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weiming Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.